Skip to main content
Scholars@Duke
Menu
About
Schools / Institutes
Browse
Jennifer Sherwin
Assistant Professor of Pediatrics
Pediatrics, Critical Care Medicine
jennifer.sherwin@duke.edu
Research
More About This Person
glance {hide_children: true, active: false, enabled: true}
At a Glance
credentials {hide_children: true, active: false, enabled: true}
Credentials
Education
Training & Certifications
academic-experience {hide_children: true, active: false, enabled: true}
Academic Experience
Current Appointments & Affiliations
Previous Appointments & Affiliations
Leadership & Clinical Positions
expertise {hide_children: true, active: false, enabled: false}
Expertise
research {hide_children: false, active: true, enabled: true}
Research
Selected Grants
publications {hide_children: true, active: false, enabled: true}
Publications
Selected Publications
artistic-works {hide_children: true, active: false, enabled: false}
Artistic Works / Events
teaching {hide_children: true, active: false, enabled: false}
Teaching
advising-mentoring {hide_children: true, active: false, enabled: false}
Advising & Mentoring
recognition {hide_children: true, active: false, enabled: false}
Recognition
professional-activities {hide_children: true, active: false, enabled: false}
Professional Activities
Manage Profile
Embed Profile Data
Manage Profile
Embed Profile Data
Selected Grants
A PHASE 2A, 2-PART, OPEN-LABEL, NON-RANDOMIZED, MULTICENTER, SINGLE AND MULTIPLE DOSE TRIAL TO EVALUATE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF AZTREONAM AND AVIBACTAM
Clinical Trial
Principal Investigator ·
Awarded by Pfizer, Inc. ·
2024 - 2026
A Phase 3, Multicenter, open-label, randomized, comparator controlled trial of the safety and efficacy of dalbavancin versus active comparator in pediatric subjects with acute bacterial skin and skin structure infections.
Clinical Trial
Principal Investigator ·
Awarded by Allergan, Inc. ·
2020 - 2024
CAZ-AVI (Ceftazidime-Avibactam)
Clinical Trial
Principal Investigator ·
Awarded by Pfizer, Inc. ·
2019 - 2022
Pharmacokinetics of a Single-Dose of Dalbavancin in Preterm Neonates to Infants Ages 3 Months with Suspected or Confirmed Bacterial Infection
Clinical Trial
Principal Investigator ·
Awarded by Allergan, Inc. ·
2016 - 2019
